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The tumor suppressor protein retinoblastoma (RB) is mechanistically linked to suppression of transcription factor E2F1mediated cell cycle regulation. For multiple tumor types, loss of RB function is associated with poor clinical outcome. RB
action is abrogated either by direct depletion or through inactivation of RB function; however, the basis for this selectivity
is unknown. Here, analysis of tumor samples and cell-free DNA from patients with advanced prostate cancer showed that
direct RB loss was the preferred pathway of disruption in human disease. While RB loss was associated with lethal disease,
RB-deficient tumors had no proliferative advantage and exhibited downstream effects distinct from cell cycle control.
Mechanistically, RB loss led to E2F1 cistrome expansion and different binding specificity, alterations distinct from those
observed after functional RB inactivation. Additionally, identification of protumorigenic transcriptional networks specific to
RB loss that were validated in clinical samples demonstrated the ability of RB loss to differentially reprogram E2F1 in human
cancers. Together, these findings not only identify tumor-suppressive functions of RB that are distinct from cell cycle control,
but also demonstrate that the molecular consequence of RB loss is distinct from RB inactivation. Thus, these studies provide
insight into how RB loss promotes disease progression, and identify new nodes for therapeutic intervention.

Introduction

The function of the retinoblastoma tumor suppressor (RB) in
preventing tumor development relies in large part on the capacity of this transcriptional corepressor to modulate E2F family
transcription factor activity (1, 2). The E2F family consists of 8
members, generally separated into 3 classes: typical activators
(E2F1–E2F3a), canonical repressors (E2F3b–E2F6), and atypical
repressors (E2F7 and E2F8) (2–4). Activator E2Fs use dimerization partners to bind DNA at promoter regions of target genes,
and induce transcriptional programs that result in a myriad of
outcomes, including cell cycle progression and DNA repair
(5–7). In conditions favoring cell cycle arrest (e.g., nutrient
deprivation), activator E2Fs are held inactive through association with RB (4), whereas pro-proliferative signals (e.g., growth
factor stimulation) inactivate RB function through cyclindependent kinase–mediated (CDK-mediated) phosphorylation,
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thus releasing RB from activator E2F1 binding and derepressing
E2F1 activity (8, 9). While RB is capable of modulating both activator and repressor E2Fs (2–4, 10), clinical observations to date
suggest that the tumor suppressor role of RB depends on modulation of activator (rather than atypical or repressor) E2F family
members, suggesting divergent functions of the E2F transcription factors in tumorigenesis (3).
Illustrating the importance of RB in restraining E2F1 function, pathways that abrogate RB-mediated E2F regulation are frequently perturbed in human tumors. In a large subset of tumors
retaining RB expression, alterations in cyclin-CDK pathways serve
to inactivate tumor suppressor function. This is achieved either via
upregulation of RB-inhibiting cyclin-CDK complex components
(e.g., cyclin D1, CDK4, and cyclin E)(11–16) or through loss of
CDK inhibitors such as p16INK4A and p27Kip1, both of which serve as
tumor suppressors in their own right through this function (11, 15–
23). Underscoring the importance of RB inactivation in promoting
cancer cell phenotypes, CDKs have been identified as therapeutic
targets, and clinical trials for CDK inhibitors have shown promise
across cancer types (NCT01291017, non–small cell lung carcinoma; NCT00141297, lymphoma; NCT01958021, MONALEESA-2,
breast cancer) (11, 24–26), with palbociclib (CDK4/6 inhibitor)
jci.org   Volume 128   Number 1   January 2018
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Figure 1. RB loss is frequent in CRPC and can be detected in circulating tumor DNA. (A) Mutual exclusivity plot indicating presence or absence of multiple
alterations with each sample in the SU2C cohort (left) and frequency of indicated alterations in SU2C CRPC cohort (n = 144, right). CNA, copy number
alteration. (B) Prevalence of specific RB alterations. (C) Schematic of ctDNA collection and sequencing of CRPC samples by the Karolinska Institute (top)
and copy number alterations in RB pathway genes identified within the Karolinska ctDNA cohort through sequencing of a 1.3-Mb panel (bottom left) and
prevalence of specific RB alterations (bottom right).

recently attaining FDA approval in hormone receptor–positive,
HER2-negative, metastatic, or advanced breast cancer (27).
Distinct from tumors that preferentially retain RB expression
but attenuate function through CDK-mediated RB inactivation, a
subset of human malignancies preferentially abrogate RB through
direct depletion of the protein. While tumor-specific proclivities
for favoring RB retention and inactivation via CDKs versus RB
loss have long been appreciated (15, 16, 28–30), the underlying
basis for selectivity is unknown, and the relative impact on downstream E2F1 signaling and function remains undefined. RB loss
is typically achieved through genetic alterations including either
genomic deletion and loss of heterozygosity or somatic mutations
that generate an unstable protein (8, 15, 29, 30). Such observations
342
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are frequent in the majority of small cell lung cancers (29, 31, 32)
as well as in the genitourinary cancers (15, 29, 30, 33–35), wherein
30%–60% of bladder and advanced prostate cancers exhibit RB
loss. In the case of prostate cancer, RB loss occurs predominantly
at the time of progression from primary disease to aggressive,
metastatic castration-resistant prostate cancer (CRPC) (30, 33,
34, 36), indicating a role in promoting tumor progression rather
than in tumor development.
Here, examination of RB pathway alterations in advanced
prostate cancer revealed that CDK/cyclin/CDKi alterations are
infrequent, and identified RB loss as the major mechanism of
pathway disruption in human disease. Furthermore, RB status
was readily traced through cell-free DNA analyses in human
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specimens, thus identifying new ways to assign RB status in the
clinical setting. Strikingly, RB depletion in human disease was
not associated with a higher Ki67 index, indicating a role for the
RB/E2F1 pathway in regulating processes distinct from cell cycle
control and associated with lethal-stage disease. Subsequent
mechanistic investigation used isogenic prostate cancer models,
wherein RB could be differentially inactivated through depletion
or through hormone-induced, CDK-mediated phosphorylation.
Unbiased molecular interrogation uncovered a novel E2F1 cistrome and downstream engagement of transcriptional networks
exclusively observed after RB loss, with binding specificity divergent from canonically described E2F1 binding patterns. Additionally, E2F1 cistrome alterations elicited by RB depletion were
seen to be distinct from those after phosphorylation-induced RB
functional inactivation, providing needed insight into the basis of
selectivity for RB loss versus CDK-mediated inactivation observed
in human disease. Analyses of human CRPC tumor samples further underscored the clinical relevance of RB loss–induced gene
expression programs, which were significantly correlated with
reprogrammed E2F1 binding identified herein. Taken together,
the studies presented are, to our knowledge, the first to identify
the consequence of RB loss, demonstrating molecular distinction
from RB inactivation and illustrating the clinical relevance of RB
loss–induced E2F rewiring.

Results

RB/E2F1 pathway disruption is frequent in and preferentially occurs
through RB loss in CRPC. RB loss has been previously described to
be prevalent in, enriched in, and causative for CRPC (34, 36–38).
To expand analyses of the RB pathway to recent clinical findings,
alterations in the androgen receptor (AR), RB, cyclin-CDK, and
CDK inhibitor profiles were assessed using a cohort of CRPC tissue from the Stand Up to Cancer/Prostate Cancer Foundation
(SU2C/PCF) prostate cancer collection (Figure 1, A and B, and
ref. 39). As expected based on the known role of the AR in promoting disease progression (40), AR amplification was observed
in 30.5% (44/144) of tumors analyzed. RB1 alterations were also
highly prevalent, with 35.4% (51/144) exhibiting single-copy RB
deletion, 1.4% (2/144) dual-copy RB deletion, and 0.7% (1/144) RB
mutation (Figure 1, A and B). Strikingly, previous tumor profiling of
late-stage disease has suggested that single-allele loss of RB is sufficient to decrease RB transcript levels, supporting the significance
of heterozygous RB loss observed in the current study (36). By
contrast, RB-related pocket proteins p107 (RBL1) and p130 (RBL2)
were rarely altered (1% and 12%, respectively; Figure 1, A and B).
There was a similar paucity of alterations in other RB pathway
genes, including CDK2, CDK4, CCND1 (cyclin D1), and CDKN2A
(p16INK4A), demonstrating that loss of RB itself is the major mechanism of RB pathway dysfunction in CRPC. Analyses of exclusivity
further demonstrated that RB pathway alterations were typically
specific to loss of the RB locus, reinforcing the concept that RB
pathway dysfunction is frequent and is predominantly achieved via
RB loss (Figure 1, A and B).
To further assess RB pathway status in advanced disease, a
second, independent cohort was examined for RB pathway alterations through isolation of cell-free tumor DNA (ctDNA) from
CRPC patients, followed by sequencing of a 1.3-Mb panel (Figure
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1C, top). As shown in Figure 1C, RB copy number alterations were
similarly frequent, with 56.4% (22/39) exhibiting loss of a single
allele, 5.1% (2/39) loss of both alleles, and 2.5% (1/39) RB mutation (Figure 1C, bottom). Further, with respect to alterations in
AR as well as other RB pathway gene members, relative frequencies were similar to what was observed in the SU2C/PCF cohort
(Figure 1A), suggesting that liquid biopsy via ctDNA may provide a
mechanism to assess RB status in this tumor type. Together, these
data indicate that genomic RB loss is preferentially enriched as
the main mechanism of RB pathway disruption in CRPC, further
underscoring the importance of RB loss in late-stage disease.
RB loss is not associated with hyperproliferative indices. Prostate cancer is well described as a heterogeneous disease (41).
As such, RB status and the extent of tumor heterogeneity were
assessed in available CRPC cohorts, wherein access to tissue
for immunohistochemistry (IHC) was available. Briefly, 107
CRPC tumor samples, collected by the Prostate Cancer Research
Center at the University of Tampere, were examined for RB1
status, AR amplification, PTEN status, and Ki67 positivity. As
exemplified in Figure 2A (left) and quantified in the right panel,
heterogeneity was observed in RB positivity. Tumors with the
highest level of RB intensity (IHC scores 16–20 and 21–25) exhibited less than 25% as much heterogeneity as tumor cells without detectable RB, whereas a minority of tumors with reduced
RB intensity (IHC scores 6–10 and 11–15, representing 21% of
tumors analyzed) demonstrated the highest level of heterogeneity (Figure 2A, right). On balance, these data demonstrate that
while heterogeneity in protein expression is observed, the majority of RB-positive tumors in the current cohort exhibit clear RB
staining across the specimens, allowing for segregation into RBpositive versus RB-low tumor sets.
Given the known role of the RB/E2F pathway in regulating cell cycle progression (1), the impact of RB loss on proliferative indices was assessed. As shown, there was no significant
correlation between Ki67 positivity and RB positivity (ρ = 0.14,
P = 0.31; Figure 2B, left), suggesting that the aggressive nature
of RB-deficient tumors cannot simply be attributed to a hyperproliferative phenotype. As some heterogeneity was observed for
RB staining, weighted RB intensity score was also considered,
thus taking into account variations seen within tumor samples.
Further supporting a role for RB outside of proliferative control,
there was no significant correlation between weighted RB score
and Ki67 positivity (ρ = 0.13, P = 0.35; Figure 2B, right). RB loss
did not correlate with other clinically relevant alterations including AR amplification or PTEN status (Supplemental Figure 1A;
supplemental material available online with this article; https://
doi.org/10.1172/JCI93566DS1), concordant with data from the
SU2C/PCF cohort (Figure 1A) wherein AR amplification was
largely observed in RB-intact tumors (30/44 tumors exhibiting
AR amplification displayed intact RB). As neuroendocrine prostate cancer (NEPC) is characterized by loss of RB coupled with
increased proliferative rates (42–44), it is of note that tumors
within this cohort did not exhibit prevalent neuroendocrine features, as confirmed through pathologic assessment. Additionally,
no association was determined between treatment and either RB
or Ki67 positivity, suggesting that treatment type did not significantly affect these correlates within this cohort (Supplemental
jci.org   Volume 128   Number 1   January 2018
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Figure 2. RB loss elicits effects outside proliferative control. (A) Left: Representative images from CRPC tissue obtained via tissue microarray (University
of Tampere) through IHC staining and RB status categorized by IHC score. IHC score = (frequency score × low intensity score) + (frequency × mid intensity
score) + (frequency × high intensity score). Each core represents a ×6 original magnification, and each inset a ×40. Right: Grouped scatterplot illustrating
quantity of RB loss within each grouping of IHC scores to illustrate RB heterogeneity. (B) Scatterplot of percent Ki67 positive versus percent of sample RB
positive (left) or RB weighted intensity score (right) within the Tampere CRPC tumor cohort, with correlation shown (Spearman ρ and P value included). (C)
Scatterplot comparing Ki67 positivity versus RB positivity (left) and weighted RB score versus percent Ki67 positive (right) within The Institute of Cancer
Research CRPC tumor cohort.

Figure 1B). Finally, an additional cohort of CRPC tumors was
examined for RB and Ki67 expression via IHC (n = 57, confirmed
to include no NEPC). Confirming results in Figure 1B, this second
cohort of CRPC tumors also exhibited no correlation between
Ki67 positivity and RB positivity (ρ = –0.061, P = 0.65) or weighted
RB intensity (ρ = 0.047, P = 0.73), further suggesting a role for
RB outside of canonical proliferative capacity (Figure 2C). Taken
together, these findings indicate that in the clinical setting, RB
344

jci.org   Volume 128   Number 1   January 2018

loss promotes CRPC phenotypes through mechanisms expanding
beyond that of cell cycle control.
RB loss results in E2F1 repositioning and expansion of the E2F1
cistrome. RB tumor suppressor function is thought to be contingent on constraining E2F transcriptional activity (1). Given the
impact of RB loss on CRPC development without influencing
proliferative indices, coupled with the known increases in both
E2F1 transcript and protein expression after RB loss, unbiased
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genome-wide assessment of E2F1 activity was prioritized (36). For
these studies, well-characterized isogenic models of RB depletion
in human prostate cancer cells (shCON and shRB, Figure 3A, top
left; and refs. 36, 38) were used for E2F1 chromatin immunoprecipitation followed by deep sequencing (ChIP-Seq). Statistically
significant E2F1 binding was identified in each isogenic line using
the model-based analysis of ChIP-Seq (MACS2) algorithm with a
stringent cutoff (Q < 0.01). With respect to shCON cells containing intact RB in castrate conditions, 11,670 peaks were detected
for E2F1 (Figure 3A, bottom left, red circle), consistent with previous studies of E2F1 binding in other models (Supplemental Figure
2A and refs. 45, 46). Interestingly, upon RB knockdown in these
same castrate conditions, the total number of E2F1-bound regions
was substantially increased to 26,431 sites, suggesting that RB
loss increases overall E2F1 binding capacity (Figure 3A, bottom
left, blue circle). It is of note that over 90% of E2F1 binding sites
observed in the presence of RB were retained after RB loss, consistent with the concept that E2F1 may exhibit gained functions upon
RB loss. Further, commonly bound sites exhibited higher binding intensities upon RB knockdown, suggesting differential E2F1
binding capacity even at commonly bound sites (Figure 3A, right).
Together, these data support an expansion of the E2F1 cistrome
rather than a simple relocation of the existing chromatin-bound
E2F1 following RB loss.
To further assess the hypothesis that RB loss rewires the E2F1
cistrome, sites of E2F1 binding gained upon RB loss were validated
in an additional isogenic model of RB loss in the background of
hormone therapy–sensitive LAPC4 cells (Supplemental Figure
2B). Additionally, validation was also performed in LNCaP-abl
cells, which are derived from LNCaP models, but incurred loss
of RB as a function of the transition to castration resistance (47).
As shown in Supplemental Figure 2B, E2F1 binding after RB loss
was validated across these models at the indicated loci, suggesting
that the E2F1 rewiring displayed in LNCaP models is maintained
in model systems. Further, to determine the potential effect of
the mechanism by which RB is modulated on E2F1 occupancy,
recently described genome-wide E2F1 binding in the LNCaP-abl
model was compared with E2F1 binding in the LNCaP shRB line.
Strikingly, over 70% of the shRB E2F1 cistrome identified in the
current study was validated by E2F1 binding in LNCaP-abl cells,
further supporting the conclusion that the expansion in E2F1 binding capacity is consistent regardless of model system or mechanism of RB modulation (Supplemental Figure 2C).
To investigate the chromosomal regions to which E2F1 was
bound in each condition, cis-regulatory element annotation system (CEAS) analysis was performed. As expected, in shCON
cells harboring intact RB, 49.6% of the total binding was determined to occur at promoter regions (“shCON castrate,” Figure
3B). Conversely, upon RB knockdown, E2F1-bound promoter
regions comprised only 26.6% of the total binding events, while
distal intergenic and intronic regions consisted of 21.9% and
22.3% of the total binding, respectively (“shRB castrate,” Figure
3B), suggesting that RB loss–induced E2F1 chromatin association
may be enriched at sites other than promoters, such as enhancers. To more fully characterize the E2F1 sites gained exclusively
after RB loss, CEAS analysis was performed (“shRB exclusive,”
16,292 sites). Remarkably, these novel E2F1-bound regions
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occurred less frequently at promoter regions (15.7%), while 31.2%
of binding occurred at intronic regions and 32.6% at distal intergenic regions, further suggesting that the E2F1 sites gained upon
RB loss largely occur outside promoter regions and may occur
at enhancer regions (Figure 3B). Combined, these data provide
some of the first insight into genome-wide E2F1 activity after RB
loss, and demonstrate that RB depletion induces significant E2F1
cistromic reprogramming.
Given these unexpected findings, the underlying mechanisms
of differential E2F1 action were investigated. De novo motif analyses were initially performed on each data set using a narrow window of 50 bp around the center of binding to specifically highlight
the characteristics of DNA sequences underlying E2F1 binding
(Figure 3C, schematic). As expected, motifs closely resembling
the well-described canonical E2F1 binding motif were among the
top most enriched motifs in shCON E2F1-bound regions (Figure
3C, top). Interestingly, motif analysis using either the full E2F1
cistrome identified upon RB knockdown (“shRB E2F1 binding”) or
the subset of E2F1-gained regions seen exclusively in the RB loss
condition (“shRB exclusive E2F1 binding”) showed enrichment
for an abbreviated form of the canonical E2F1 motif lacking a 5′
poly-T stretch (Figure 3C, middle and bottom). Importantly, recent
studies have shown E2F1 to have the ability to bind this truncated,
previously described minimum-affinity E2F1 motif in specific conditions (such as in the context of sustained E2F1 activity) (46, 48).
Thus, these data suggest that in the context of intact RB, E2F1 is
bound to primarily “high-affinity,” canonical E2F1 motifs, while
RB loss drives E2F1 binding to a “minimum-affinity” motif.
To further assess the means by which E2F1 is directed to new
sites upon RB loss, cooperating factor motifs were investigated.
For these analyses, a broader window around the center of binding (1,000 bp) was applied to the E2F1 cistromes identified herein
to examine the potential for changes in cooperative factor interactions, contingent on RB status. As expected, enrichment for
canonical E2F motifs was depleted upon RB knockdown (Figure
3D, left, and Supplemental Figure 3), further supporting the idea
that RB loss induces E2F1 binding distinct from canonical regions.
Moreover, motifs belonging to the E2F family of transcription factors represented the majority of those enriched in binding sites
exclusive to the control condition (Supplemental Figure 3). Additionally, as the E2F1 cistrome exhibited a marked expansion upon
RB loss, motifs specifically enriched in these regions were identified. To identify potential novel functional interactions, motifs
with enrichment detected in control conditions were removed,
leaving those exclusively associated with gained binding upon
RB loss (Figure 3D, right). Strikingly, motifs enriched exclusively
adjacent to E2F1 binding after RB loss consisted of several transcription factor binding motifs, including NF1, the TLX nuclear
receptor, and AR. These findings not only provide the first evidence for the role that RB depletion may have in driving E2F1 to
minimum-affinity sites, but also suggest that novel cooperating
transcription factors likely assist E2F1 to mediate phenotypes
associated with RB loss.
E2F1 function is distinct after RB depletion versus RB inactivation.
Dihydrotestosterone (DHT) is a potent ligand for AR in prostate
cancer, and has been previously shown to induce RB hyperphosphorylation and subsequent inactivation through AR-dependent
jci.org   Volume 128   Number 1   January 2018
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Figure 3. RB loss expands E2F1 binding capacity and repertoire of associated cis-binding elements. (A) Overlap of binding in shRB or shCON cells in
castrate conditions. (B) Cis-regulatory element analysis of shCON or shRB
binding data sets determined using CEAS package. Percent of total binding
is shown in indicated data sets. (C) De novo motif enrichment using a 50-bp
window around the center of binding. Enrichments specific to the data set
are shaded in the Venn diagrams with P values shown for each motif. (D)
Left: JASPAR (http://jaspar.genereg.net/) E2F1 motif was used to determine
enrichment in shCON E2F1 or shRB E2F1 binding data set using a 1,000-bp
window around the center of binding. Right: Top motifs enriched only in
shRB exclusive data set using known motifs and a 1,000-bp window around
the center of binding and representative histogram of motif enrichment.

signaling (49, 50), thus serving as a mitogen in prostate cancer. To
determine whether inactivation of RB through DHT stimulation is
distinct from the changes seen upon RB depletion, E2F1 binding
was assessed through additional ChIP-Seq binding studies after
3-hour DHT stimulation, which resulted in subsequent RB phosphorylation and inactivation in shCON cells (Supplemental Figure 4A). Similarly to RB knockdown, DHT stimulation resulted in
an expansion of the E2F1 cistrome, with 21,510 sites gained after
DHT stimulation in comparison with control (Figure 4A, orange
circle and red circle, respectively). To further address the impact
of hormone action on E2F1 activity, estrogen-dependent breast
cancer cells were stimulated with estradiol, which has been previously shown to induce RB phosphorylation through cyclin D1/
CDK4 activity (51–54), and the impact on E2F1 was assessed on
a tested subset of sites exhibiting increased E2F1 occupancy after
DHT stimulation. As shown, E2F1 binding after estradiol treatment in MCF7 cells shows similar increases in occupancy, demonstrating that hormone-induced E2F1 rewiring is not exclusive
to prostate cancer (Supplemental Figure 4B). Additionally, while
21,026 binding sites were commonly occupied between the RBloss (shRB castrate) and RB-inactivated (shCON 3-hour DHT)
conditions, a significant fraction of E2F1 binding sites were differentially occupied in both shRB castrate conditions (5,374 sites)
and RB-inactivated conditions (10,592 sites) (Figure 4A). These
findings additionally underscore the concept that the molecular repercussions of RB loss are distinct from those of mitogenic
stimuli–induced RB inactivation. Further, as RB loss alone in current models has been shown to significantly rewire E2F1 binding
(Figure 3), the potential for androgen stimulation to further alter
the E2F1 cistrome was tested. Interestingly, over 86% of sites
identified in shRB models after DHT stimulation were common
with those identified after RB loss alone, indicating that stimulation with androgens does not significantly alter E2F1 binding
after RB loss, consistent with RB loss itself being a major driver of
CRPC (Supplemental Figure 4C).
Moreover, as E2F1 binding transitioned from canonical promoter regions upon RB depletion (Figure 3B), changes in regulatory elements near E2F1 binding upon RB inactivation were
assessed. As shown in Figure 4B, 46.4% of E2F1 binding occurred
at promoter regions upon DHT-induced RB inactivation, similar
to the 49.6% bound to promoters with intact RB (shCON castrate),
whereas only 26.6% of binding was seen at promoters upon RB
depletion (shRB castrate). Consistently, only 9.5% and 9.0% of
the total binding was seen at intronic and distal intergenic regions
upon RB inactivation, respectively, as compared with 22.3% and
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21.9% after RB depletion. Together, these data suggest that while
DHT inactivation of RB induces an increase in overall E2F1 binding, this cistrome is distinct from that seen after RB loss with
respect to both overall binding site overlap and specific changes in
enrichment of cis-regulatory elements.
Because of the changes seen in regulatory elements associated with E2F1 occupancy between the 2 conditions, binding characteristics after RB depletion versus inactivation were assessed
through de novo motif enrichment to highlight changes in DNA
sequences underlying differential binding. While the CTCF binding motif was enriched in both data sets, other key distinctions
were observed. Whereas the E2F1 cistrome after RB inactivation
was enriched for E2F1 and FOXM motifs (Figure 4C, top right),
E2F1 binding after RB depletion was most associated with nuclear
receptor motifs (Figure 4C, bottom right). Together, these findings further indicate that RB inactivation through DHT stimulation and RB loss elicit divergent E2F1 binding profiles, with regard
to both promoter preference and binding specificity.
Chromatin accessibility is equivalent regardless of RB status.
RB and E2F1 have both been described to interact with chromatin remodelers in various cellular contexts to alter the chromatin
landscape (48, 55–58). Coupled with the finding that E2F1 binding is significantly expanded after RB loss, and that this expansion
is distinct from E2F1 binding after DHT-induced RB inactivation,
the potential for differential chromatin accessibility was assessed
using assay for transposase-accessible chromatin with highthroughput sequencing (ATAC-Seq). ATAC-Seq uses hyperactive
Tn5 transposase activity to preferentially insert adapters (used for
high-throughput sequencing) in regions of open chromatin. Thus,
in order to assess chromatin availability in conditions displaying
the greatest changes in E2F1 binding, ATAC-Seq was performed in
shRB and shCON cells in castrate conditions, as well as in shCON
cells in DHT-stimulated conditions. As seen in Figure 5A, regions
of open chromatin were detected across conditions in both promoter and distal regions of the indicated E2F1 targets, consistent
with the capacity for this assay to identify regions of open DNA.
To detect regions of accessible DNA on a genome-wide scale,
ATAC-Seq peaks were called in each condition, applying the irreproducible discovery rate (IDR) framework in order to ensure
high-confidence peaks. The majority of peaks identified were
present in all tested conditions tested (7,308 sites; Figure 5B, left),
suggesting that while there are minor changes in open chromatin
peaks observed, the chromatin landscape remains highly similar
regardless of RB status or androgen stimulation. Further supporting this conclusion, normalized ATAC-Seq signal remained present across the merger of all peaks identified in all conditions, with
the highest binding intensity seen in DHT-induced RB-inactivated
conditions, likely due to changes outside RB/E2F1 activity, and the
weakest in castrate control conditions (Figure 5B, right). Finally,
principal component analysis was performed to assess variability
between the conditions on a genome-wide scale. As shown in Figure 5C, each condition displays similar segregation along principal
component 1 (x axis), which represents over 90% of the variance
seen across the samples (Figure 5C and Supplemental Figure 5),
further supporting the similarity between conditions with respect
to open chromatin. Together, these data demonstrate that the
overall state of chromatin accessibility remains similar after RB
jci.org   Volume 128   Number 1   January 2018
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Figure 4. DHT-mediated RB inactivation results in distinct E2F1 reprogramming. (A) Overlap of binding in LN shCON cells in androgen-stimulated conditions (3-hour DHT) with shCON or shRB cells in castrate conditions. (B) Chromosomal enrichment analysis of castration-treated or DHT-stimulated cells,
represented as percent of total binding in each indicated data set. (C) De novo motif enrichment in indicated data sets using a 50-bp window around the
center of binding using binding exclusive to either the shCON DHT-stimulated condition (top) or the shRB castrate condition (bottom).

depletion or inactivation, and support the idea that E2F1 rewiring
is likely not due to widespread global alterations in open chromatin and indiscriminate or opportunistic E2F1 binding.
Delineation of the RB loss–induced transcriptome. The observations that RB loss in CRPC is frequent and not correlated with
a hyperproliferative phenotype (Figures 1 and 2), coupled with
the finding that RB loss induces expansion of the E2F1 cistrome
(Figure 3) distinct from that seen with inactivation of RB and via
mechanisms outside differential chromatin accessibility (Figures
4 and 5), suggest that RB loss alters E2F1 activity in prostate cancer, and likely results in differential regulation of transcriptional
networks that promote disease aggressiveness. Strikingly, there
have been few reports that assess genome-wide E2F1 activity
and resultant transcriptional outcomes in any tumor type, and to
our knowledge no genome-wide assessment of E2F1 activity after
348
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RB loss. As such, RNA from shCON and shRB isogenic pairs was
isolated and RNA sequencing (RNA-Seq) performed. Significant
transcriptional alterations were seen in castrate conditions, with
1,423 genes upregulated and 1,496 downregulated genes observed
after RB loss (adjusted P value < 0.05; Figure 6A). Consistent with
the role of E2F1 as a transcriptional activator, RB loss was seen to
induce the transcription of a number of different genes, including
previously described E2F1 targets such as PCNA and PLK1 (Supplemental Figure 6A). The abundance of transcripts downregulated upon RB knockdown was less anticipated, and suggests that
E2F1 may directly or indirectly serve as a transcriptional repressor as well (Figure 5A, left, and Supplemental Figure 6A). To test
RB loss–induced transcriptional changes across model systems,
LAPC4 isogenic models (shCON/shRB) and LNCaP-abl models
were also assessed for transcriptional changes (both up- and down-
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Figure 5. Chromatin landscape is consistent regardless of RB status. (A)
ATAC-Seq signal at indicated loci for shCON and shRB in castrate conditions and shCON after DHT treatment using Integrative Genomics Viewer
(http://software.broadinstitute.org/software/igv/home). (B) Venn
diagram representing overlap in ATAC-Seq peaks (left) and ATAC-Seq
signal across all peaks in all conditions (right). Peak calling was performed
using the ATAC-Seq ENCODE pipeline, and highly concordant peaks across
replicates were identified using IDR and subsequently used for Venn
diagram and signal profile generation. (C) Principal component analysis
for ATAC-Seq replicates.

regulated) at the indicated targets. Targets assessed were seen to
exhibit highly concordant changes in gene expression after RB
loss, as compared with LNCaP isogenic lines, thus indicating a
high degree of reproducibility across multiple model systems and
mechanisms of RB loss (Supplemental Figure 6A). Additionally, to
assess the potential for CDK4/6 inhibitors to enhance transcriptional alterations identified in RB loss versus RB-intact conditions,
shCON cells were treated with a CDK4/6 inhibitor (palbociclib),
and gene expression in a subset of RB loss–induced targets was
examined. As expected, no significant effect was seen on gene

expression after CDK4/6 inhibitor treatment compared with castrate conditions, suggesting that castrate conditions fully activate
RB in the context examined (Supplemental Figure 6B). Finally,
as DHT stimulation was seen to have little added effect on E2F1
binding after RB loss alone (Supplemental Figure 4B), the potential
for DHT to further deregulate the RB loss–induced transcriptome
was tested. As shown in Figure 6B, no significant alterations
were identified in shRB cells in castrate versus DHT-stimulated
conditions, consistent with the supposition that RB loss itself
represents the main mechanism of transcriptional deregulation.
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Figure 6. Genome-wide assessment of RB loss reveals novel functions
and distinct transcriptional profiles. (A) Smear plot for RNA-Seq in
castrate conditions (shRB vs. shCON) using Empirical Analysis of Digital
Gene Expression Data in R (edgeR) to define differentially expressed
genes. Genes highlighted in red represent statistically significant differential expression (adjusted P value < 0.05). CPM, counts per million
reads mapped (B) Smear plot for RNA-Seq in shRB models (castrate vs.
DHT-stimulated conditions) using edgeR to define differentially expressed
genes. Genes highlighted in red represent statistically significant differential expression (adjusted P value < 0.05). (C) GSEA for enriched pathways
upon RB loss (normalized enrichment score [NES] > 1.3). Briefly, transcriptional data from RNA-Seq output were examined for overrepresented
pathways using the Hallmarks gene set collection (Molecular Signatures
Database, MSigDB). Pathways de-enriched (left) or enriched (middle)
after RB loss are shown, and leading-edge plot for E2F targets (right). (D)
Schematic of binding to gene association with overlay with gene expression data. (E) Intersection of pathways identified from RNA-Seq alone
compared with those identified using the intersection of RNA-Seq and
ChIP-Seq results (NES > 1.3).

To identify pathways that were deregulated upon RB loss, gene
set enrichment analysis (GSEA) was performed, using hallmark
gene sets from the Molecular Signatures Database (MSigDB). Few
pathways were attenuated after RB depletion, despite the total
number of genes altered in this category, underscoring the focused
nature of E2F1 activity to elicit specific transcriptional programs.
Pathways with attenuated enrichment include those that have
been previously shown to interplay with the RB/E2F1 axis, such
as epithelial-mesenchymal transition, hedgehog signaling, and
myogenesis (Figure 6C, left; normalized enrichment score < –1.3)
(59–64). Conversely, a number of clinically relevant pathways
were enriched upon RB loss, including canonical E2F targets, Myc
targets, mitotic spindle, and DNA repair (Figure 6C, right; normalized enrichment score > 1.3). The observed induction of E2F targets upon RB depletion was especially striking given the absence
of mitogenic stimuli typically required to promote transcription of
these targets. Similarly, the increased transcriptional output for
genes responsible for DNA repair suggests that putative gained
functions of E2F1 upon RB depletion may drive dysregulation of
genes controlling DNA damage response, even in the absence of
DNA damage. Further, Myc has been shown in other tumor types
to interact with E2F3 to bring about specific transcriptional programs important for cancer progression (65). Here, transcriptional
data provide some of the first evidence for RB loss–driven induction of Myc targets in prostate cancer, validated in multiple model
systems, suggesting that E2F1 rather than E2F3 may interact with
Myc in this disease type (Supplemental Figure 6A).
Further, to test for concordance with previously described
signatures of RB loss of function, GSEA was performed using a
previously described “RB loss signature” (66). As shown in Supplemental Figure 6C, genes in the RB loss signature were highly
enriched within RB loss–induced transcriptional alterations
seen in the current study, suggesting that RB loss in the current study encompasses previously described gene expression
changes after functional RB inactivation. Finally, as previous
studies have shown AR targets to be impacted by RB loss (36),
a signature of androgen response generated from patient tissue
was assessed for enrichment in the current model (67). Consistent with the previously described role for RB loss to alter AR
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signaling, the RB loss–induced transcriptome was significantly
enriched for this gene signature (Supplemental Figure 6D).
Taken together, the transcriptional changes seen upon RB depletion demonstrate gained E2F1 activity in the absence of canonically required stimuli to elicit transcriptional profiles known to
be vital for aggressive disease.
To determine the potential mechanism driving the transcriptional changes observed after RB depletion, genes associated
with changes in E2F1 binding after RB loss were assessed using
a guilty-by-association approach (68). Briefly, to identify genes
potentially regulated by novel binding, as the majority of gained
binding was seen away from promoter regions, a 30-kb window
around gene transcriptional start sites was used, with genes within
this window deemed putatively regulated by E2F1 binding exclusive to each condition (shCON castrate, shRB castrate; Figure 6D,
left). Using this approach, 317 genes showed exclusive E2F1 binding within this window with RB intact, while 599 genes harbored
a gained E2F1 site in both RB-intact and RB-depleted conditions,
and 12,269 genes were associated with a gained E2F1 binding site
exclusive to the RB loss condition (Figure 6D, middle). Next, genes
with binding exclusive to RB loss (12,269 genes) were overlaid
with those exhibiting differential expression from the RNA-Seq
previously described in Figure 6A to determine whether the novel
E2F1 binding seen after RB loss was associated with the altered
transcriptional profiles observed after RB depletion (Figure 6D,
right). To more accurately assess this, GSEA was performed
using the genes exhibiting gained E2F1 binding accompanied by
changes in gene expression, and significantly altered pathways
were compared with those identified from only transcriptional
data in Figure 6C. As shown, half of the attenuated pathways
identified from the RNA-Seq alone were also identified using
those genes with altered expression and gained E2F1 binding
(Figure 6E, left), suggesting that a subset of the pathways with
reduced enrichment are likely attributable to novel E2F1 binding–
mediated repression. Additionally, when pathways enriched upon
RB loss were investigated, 70% of the pathways initially identified using RNA-Seq alone were recapitulated when genes with
altered expression and gained E2F1 binding were analyzed (Figure 6E, right). As the RB loss–driven transcriptome has heretofore
remained undefined, the finding that the majority of the pathways
induced after RB depletion were associated with a gain in E2F1
binding is striking, and suggests a fundamental role for the novel
E2F1 cistrome identified herein as a putative driver of these pathways vital for lethal tumor phenotypes.
Evidence of expanded E2F1 activity in clinical CRPC. To assess
the clinical relevance of the newly identified transcriptional networks and E2F1 repositioning driven by RB loss, genes were prioritized through iterative processes for further analyses. Briefly, genes
exhibiting differential expression upon RB loss were segregated
into 2 categories to determine the specific importance of gained
E2F1 binding capacity clinically: (a) genes with any E2F1 binding
within 30 kb of the transcriptional start site and (b) genes specifically associated with gained E2F1 binding after RB loss (Figure
6D). These 2 gene sets were then queried against gene expression
data from the SU2C/PCF CRPC tumor cohort. Genes exhibiting
expression changes upon RB loss in the SU2C/PCF cohort concordant with our model were identified, resulting in a list of genes with
jci.org   Volume 128   Number 1   January 2018
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Figure 7. Clinical assessment of RB loss in CRPC reveals novel E2F1-gained cistrome-driven gene signature. (A) Differentially expressed genes from
RNA-Seq were overlaid with ChIP-Seq binding studies into those genes that were associated with an E2F1 binding site, or those genes associated with a
gained E2F1 binding site (seen only upon RB loss). Genes in each of these categories were then queried against CRPC patient data from the SU2C cohort,
and those genes from each category with expression concordant with the initial model identified. TSS, transcriptional start site. (B) Hierarchical clustering
of normalized expression data of concordant genes from 144 SU2C CRPC samples (1 – Pearson’s correlation coefficient for columns and Euclidean distance
for rows were used as distance measures). The annotation track reports the genomic status of RB1 (black, SCNA alteration; white, no SCNA alteration) and
genes used for heatmap generation identified through analysis in A. (C) GSEA was performed on the 80-gene signature identified in B, in order to identify
which pathways were likely to drive signaling in CRPC patients.

E2F1 binding (present or exclusively gained after RB loss), differential expression in models of RB loss, and differential expression
in clinical patient samples after RB loss (Figure 7A).
To examine the clinical relevance of RB loss–induced E2F1
reprogramming and altered transcriptional output identified in
the present study, hierarchical clustering was performed using
genes identified in Figure 6A and transcriptional data from the
SU2C/PCF CRPC tumor cohort (Figure 7A). Importantly, genes
specifically exhibiting gained E2F1 binding sites upon RB loss
(deemed “E2F1 expanded signature”) displayed a significant abil352
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ity to cluster tumors exhibiting RB loss together in the SU2C/PCF
cohort (P = 0.002, odds ratio = 3.7) compared with those genes
with the presence of an E2F1 binding site (not significant), suggesting that genes exhibiting RB loss–induced differential expression and expanded E2F1 binding in this model better predict for
RB loss in clinical samples than the simple presence of an E2F1
site alone (Figure 7B and Supplemental Figure 7A). As such, these
findings demonstrate that the capacity of RB loss to reprogram
E2F1 binding capacity and the resultant downstream transcriptional networks occurs in clinically lethal CRPC. Furthermore,
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interrogation of the resulting gene signature further highlights
the protumorigenic consequence of RB loss that is distinct from
cell cycle control. Using GSEA analyses, pathways enriched within
this signature included not only E2F targets, but also networks
regulating Myc function, mitotic spindle integrity, and p53
response (Figure 7, B and C). Further, to assess how the E2F1
expanded signature identified in the current study compared with
“ideal” clustering for RB loss in the SU2C/PCF cohort, supervised
analysis was performed using only SU2C/PCF gene expression
data to identify genes significantly changed in RB-altered versus RB wild-type samples. As shown in Supplemental Figure 7B,
clustering resulting from supervised analysis was comparable to
that generated using the E2F1 expanded signature. Moreover,
genes contained in the E2F1 expanded signature were seen to be
significantly enriched within the gene set resulting from supervised analysis by both GSEA (FDR = 0.003) and Fisher’s exact test
(P < 1 × 10 –10) (Supplemental Figure 7C), further supporting the significance of gained E2F1 binding upon RB loss within the SU2C/
PCF cohort. Together, these data demonstrate that the expanded
E2F1 cistrome identified herein occurs in RB-deficient clinical
CRPC, providing the first insight into the mechanisms by which
RB loss induces aggressive tumor phenotypes, independent of cell
cycle dysregulation (Figure 8).

Discussion

The importance of the RB/E2F1 pathway in tumor suppression is
compellingly illustrated by the frequency of pathway disruption in
human malignancy and association with poor outcome (34–36, 38,
69). However, the underlying basis for tumor-specific RB inactivation versus RB loss remains unknown. The present study reveals
the molecular consequences of RB loss in human disease, and
identifies unique molecular and cellular outcomes that promote
tumor aggressiveness. Key findings include: (a) in CRPC, alterations of the RB pathway are preferentially enriched for RB loss,
which is frequently observed in both tumor samples and ctDNA
from patients with advanced disease (Figure 1); (b) loss of RB is
associated with advanced disease but is independent of altered
proliferative indices, suggesting roles for RB outside cell cycle control (Figure 2); (c) RB loss expands and reprograms E2F1 chromatin occupancy (Figure 3); (d) the molecular consequence of RB loss
is distinct from that observed after RB inactivation (Figures 3 and
4); (e) gained E2F1 binding capacity is not likely to be the result of
widespread, global changes in chromatin accessibility (Figure 5);
(f) RB depletion induces distinct transcriptional networks that are
highly associated with gained E2F1 activity after RB loss (Figure
6); and (g) the identified transcriptional programs driven by the
gained activity of E2F1 upon RB loss (“E2F1 expanded signature”)
occur in clinical, end-stage disease (Figure 7). Taken together,
these findings define the molecular and tumor-associated consequences of RB loss in human malignancy, and provide the first
insight into the putative mechanism of RB loss–induced transcriptional alterations in advanced cancers.
As demonstrated in both preclinical modeling and clinical
samples, it is clear that reprogrammed E2F1 activity after RB
loss elicits biological effects distinct from cell cycle control.
As described herein, analyses of 2 large, independent CRPC
cohorts indicate that loss of RB is the main mechanism of RB
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pathway disruption in this malignancy. While additional studies will be used to assess the potential for altered AR activity
to impact RB phosphorylation status in late-stage disease, data
in the present study reveal no correlation between loss of RB
and increased Ki67 in CRPC, demonstrating that RB loss is not
sufficient to alter proliferation and further suggesting that the
capacity of RB depletion to drive aggressive tumor phenotypes
occurs via functions distinct from cell cycle control (Figure 2,
B and C). While investigation of associations between RB pathway status and Ki67 in the clinical setting is limited, the concept
that RB loss induces biological effects distinct from cell cycle
deregulation has precedent in human tumors. For instance,
in a recent study of lung adenocarcinoma (70), RB-negative
tumors were seen to have no correlation with Ki67 positivity
(P = 0.33), further supporting findings in the current study that
suggest RB loss is not associated with hyperproliferative phenotypes (Figure 2, B and C). Conversely, in other tumor types
where RB expression is retained but inactivated by phosphorylation, correlation with a higher proliferative index was observed,
including studies in diffuse large B cell lymphoma, in Burkitt’s
lymphoma wherein p27Kip1 is lost (71, 72), or in luminal A and
triple-negative breast cancer where p16INK4A loss occurs (21).
In concert with the data herein, these findings shift thinking
with regard to RB pathway disruption, and provide compelling
clinical evidence to support the contention that RB loss is mechanistically distinct from RB inactivation.
The discovery that RB loss elicits distinct effects compared
with RB functional inactivation in clinical tumor samples is striking, as RB loss alone is sufficient to induce CRPC phenotypes (36)
and loss of RB was seen to be the main mechanism of RB pathway
disruption in the current study. Further, as models of RB loss are
reliant on E2F1 for castration-resistant growth (36), provision of
a putative mechanism for E2F1 in mediating these downstream
phenotypes is significant. Toward this end, a key discovery herein
demonstrated, through use of multiple model systems, is that
the E2F1 cistrome is differentially expanded after RB loss, suggesting that E2F1 binding is not in fact a static phenomenon.
Further, studies presented here demonstrate, for the first time to
our knowledge, that RB loss (as compared with RB inactivation)
significantly expands the putative repertoire of E2F1-regulated
target genes through binding outside of promoter regions, with
16,292 E2F1 sites gained after RB loss, 31.2% and 32.6% of binding
occurring in intronic and intergenic regions, respectively (Figure 3,
A and B). As E2F1 was previously thought to regulate target genes
through promoter binding (2), these findings open new avenues of
understanding for discerning the function(s) of E2F1 in promoting
disease progression when RB is lost. Moreover, as discerning the
molecular basis of expanded E2F1 binding is of interest, it is striking that chromatin accessibility was largely unchanged regardless of RB status, suggesting that the mechanisms underlying the
altered E2F1 cistrome lie outside simple opportunistic binding
due to changes in open chromatin (Figure 5). Thus, current investigation is focused on discerning the molecular basis of expanded
E2F1 binding upon RB loss.
Data herein further implicate gained E2F1 chromatin localization outside canonical promoter regions, through potential
use of a noncanonical minimum-affinity binding motif previjci.org   Volume 128   Number 1   January 2018
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Figure 8. Summary of E2F1-induced alterations upon RB loss in CRPC. (A)
Circos plot represents ChIP-Seq, RNA-Seq, and clinical alterations identified in the current study. From outer ring to inner ring, the levels represent:
(i) differentially expressed genes identified through RNA-Seq after RB loss
(purple/green heatmap), (ii) E2F1 binding exclusive to shCON condition
(blue histogram), (iii) binding common to shCON and shRB conditions
(gray), (iv) E2F1 binding exclusive to shRB condition (red histogram), and
(v) genes exhibiting differential expression after RB loss, associated with
gained E2F1 binding, and concordant with SU2C clinical expression data.
(B) Hypothesized model of RB loss in CRPC.

ously identified in studies assessing E2F1 functional domains in
addition to those investigating E2F1 function in liver cancer (refs.
46, 48, and Figure 3, C and D). Interestingly, this abbreviated,
minimum-affinity E2F motif was found to be enriched in regions
of AR binding as well as under epigenetic marks of active transcription (H3K4me3) in recent studies in CRPC tissue (67), suggesting
that E2F1 may preferentially interact with AR in CRPC through
gained binding capacity at minimum-affinity regions. Moreover,
motifs for binding of putative cooperating transcription factors of
clinical relevance were enriched in conjunction with gained E2F1
occupancy after RB loss (Figure 3D), including those associated
with: NF1 factors, which can modulate AR function (73, 74); TAL-1
(SCL), which influences pioneer factors that modulate AR function (75, 76); and the half-site for AR itself. Further, de novo motif
analyses additionally implicate AR, as the RB loss–induced E2F1
cistrome was enriched for an AR half-site (Figure 4C) (77). These
observations suggest the intriguing concept, currently being tested, that E2F1 reprogramming may influence AR activity, or vice
versa. Finally, gained E2F1 binding is associated with enrichment
for the orphan nuclear receptor TLX, which promotes prostate
cancer growth and is highly expressed in advanced disease (78).
Combined, these data indicate that loss of RB expands E2F1 activity in a manner distinct from RB retention/inactivation, allowing
E2F1 to localize to new, distal genomic sites governed distinctly
from promoter regions (Figures 3 and 4).
Consistent with the molecular identification of the differential RB-mediated E2F1 cistrome, a distinct transcriptome was
defined, which was driven specifically by RB depletion and highly
associated with E2F1 reprogramming in the context of RB loss
(Figure 5). Discovery of transcriptional networks that are uniquely
associated with expanded E2F1 occupancy underscored activities of E2F1 beyond those linked to cell cycle control (Figure 6,
C and E), and identified heretofore underappreciated functions
of E2F1. Notably, E2F1 reprogramming appears to be associated with increased Myc target gene expression, which is known
to promote disease progression and poor outcome in this tumor
type (79, 80). These findings may also provide a molecular basis
for recent observations in intestinal cancers, wherein RB pathway
loss induces E2F3 and Myc cooperation (65). As such, while E2F3
does not significantly correlate with RB loss in CRPC (36), the
potential for effects on the RB loss–induced E2F3 cistrome represents an intriguing node of future study. In addition to associations with Myc function, it is striking that E2F1 reprogramming
enriches pathways promoting DNA damage and repair, given
recent findings linking DNA repair alterations with disease progression and acquisition of aggressive tumor phenotypes (81–86).
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Together, these findings bring about broad new understanding
of the biological impact of RB loss on tumor phenotypes that promote progression; ongoing studies are directed at discerning the
relative contribution of each newly identified E2F1-associated
network to biological outcomes and disease progression.
Finally, findings in the current study identify a signature of
genes predictive for RB loss in CRPC, associated with gained E2F1
binding in the model systems used in the current study (Figure
7). Remarkably, only genes exclusively associated with expanded
E2F1 binding driven by RB loss clustered CRPC tumors deficient
in RB expression, while the simple presence of E2F1 was unable to
predict for the same alteration in the tumor samples, suggesting
that E2F1 binding gained after RB loss is significantly relevant to
CRPC phenotypes (Figure 7B and Supplemental Figure 7). These
data identify, for the first time, a set of targets induced through
novel E2F1 binding, and specifically altered by RB loss in human
disease. Importantly, higher stringency used to define differentially expressed genes in the model systems used herein identified
stronger concordance between in vitro expression data and gene
expression profiles from patient tumor samples, further highlighting the clinical relevance of the targets identified in these models. It is of note that the current study used models of AR-positive
disease in addition to non-neuroendocrine CRPC tumor samples
(SU2C/PCF), as recent studies suggest that RB loss may yield distinct effects in tumors acquiring neuroendocrine phenotypes via
RB loss (39, 87). Further, as RB loss of expression has been shown
in the current study to elicit molecular effects distinct from those
driven by phosphorylation-induced inactivation, it is likely that
this RB loss–induced gene signature (E2F1 expanded signature)
could be applied to other disease types to indicate similar E2F1
reprogramming. Additionally, pathway analyses for genes within
this signature were highly consistent with those identified using
binding and gene expression in the model systems alone, suggesting a coordinated set of pathways preferentially driven by E2F1
binding both in vitro and in advanced disease (Figure 6E and Figure 7C). Thus, the identification of specific RB loss–altered gene
targets within pathways that drive CRPC phenotypes represents
potential targets for further therapeutic intervention.
Taken together, molecular interrogation of E2F1 function
after RB loss suggests a paradigm shift, whereby E2F1 binding is directed away from promoter regions, eliciting marked
reprogramming of E2F1 chromatin-binding capacity and E2F1associated transcriptional programs. Further, data herein coupled with clinical studies indicate that E2F1 activity after RB loss
is distinct from E2F1 activity after phosphorylation-induced RB
inactivation, suggesting a distinction in how RB protein depletion and loss of function through inactivation impact human
malignancy. Finally, data in the current study nominate a novel
gene signature driven by RB loss and gained E2F1 function,
which is altered in late-stage prostate cancer and is predictive
for RB loss in advanced disease (“E2F1 expanded signature”),
further nominating E2F1 as a critical driver of CRPC phenotypes
in this disease state. Together, these findings contribute new
insights into the molecular mechanisms underpinning RB loss–
dependent CRPC phenotypes, and define a novel E2F1 cistrome
upon RB loss associated with an altered transcriptional program
with applicability to multiple malignancies.
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Methods

ChIP sequencing. ChIP was performed as described previously (88).
Briefly, 8 × 106 to 10 × 106 cells were cross-linked with 1% formaldehyde for 10 minutes at room temperature. Nuclei were extracted using
LB3 buffer (10 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA
[pH 8.0], 0.5 mM EGTA [pH 8.0], 0.1% Na-deoxycholate, 0.5% Nlauroylsarcosine), and chromatin was sheared to 200–700 bp using
Covaris E220 Focused Ultrasonicator (Covaris). E2F1 antibodies for
ChIP assays were purchased from BD Pharmingen (catalog 554213)
and Santa Cruz Biotechnology (sc-193). The ChIP-Seq libraries were
constructed using the ThruPLEX-FD Prep Kit (Rubicon Genomics) with approximately 10 ng of ChIP DNA. Final products were
sequenced on the NextSeq 500 at the Molecular Biology Core Facilities of Dana-Farber Cancer Institute. ChIP-Seq data have been deposited in the GEO repository under the accession number GSE94958.
RNA sequencing. RNA-Seq samples were prepared as described previously (47). Briefly, total RNAs were extracted and purified using the
TRIzol reagent and RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. RNA-Seq libraries were constructed using TruSeq
RNA Sample Prep Kit v2 (Illumina, RS-122-2001) and then sequenced
on the NextSeq 500 at the Molecular Biology Core Facilities of DanaFarber Cancer Institute. RNA-Seq data have been deposited in the GEO
repository under the accession number GSE94863.
ATAC-Seq. ATAC-Seq was performed as previously described
(89). Briefly, cells were plated and treated as indicated by the condition. Next, 75,000 cells were collected and lysed in ATAC lysis buffer.
Cells were then resuspended in the transposition reaction mix, and the
transposition reaction was incubated at 37°C for 30 minutes. Transposed DNA was purified using AMPure purification methods as specified by the manufacturer (Agencourt). Purified DNA was then amplified using custom barcoded Nextera primers as previously reported
and available in Buenrostro et al. (89). Library size and quality were
validated using a Bioanalyzer and libraries sequenced on a NextSeq
500. ATAC-Seq data have been deposited in the GEO repository
under the accession number GSE105116.
Androgen stimulation. In androgen stimulation conditions, cells
were cultured in 5% charcoal dextran–treated (CDT-treated) media
for 72 hours before treatment with 10 nm DHT or vehicle (EtOH) for 3
hours prior to harvest.
Quantitative PCR. Quantitative PCR (qPCR) analysis for occu
pancy was performed as previously described for both ChIP-qPCR
and reverse transcription qPCR (47, 88).
Immunoblot analysis. Cells were plated in CDT for 72 hours before
harvest. Cell lysates were generated and immunoblot performed as
previously described (68). Antibodies used were as follows: RB (BD
Pharmingen, 554136), E2F1 (Santa Cruz Biotechnology, sc-193), GAPDH (Santa Cruz Biotechnology, sc-25778), p780-RB (Cell Signaling
Technology, 3590S).
Statistics. Statistical analyses were performed as described above.
Briefly, IHC correlations were calculated by Spearman correlation,
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with a P less than 0.05 considered significant. Significance for ChIPSeq and differential gene expression for RNA-Seq were calculated by
the indicated software as described above. Motif analysis significance
was calculated by the Homer suite, with a P less than 1 × 10–20 considered significant. Concordance with the study model and SU2C/PCF
cohort was calculated as described above. Individual thresholds for
significance are additionally indicated in applicable figure legends.
Data are expressed as mean ± SD unless otherwise indicated.
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National Authority for Medicolegal Affairs (Helsinki, Finland), by the
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cases excluding samples from the Tampere cohort, where, according
to Finnish law, in cases in which informed consent cannot be obtained
as a result of studies involving large retrospective materials or patients
who have died before study, permission can be given by the National
Authority for Medicolegal Affairs.
Further information can be found in Supplemental Methods, available online with this article; https://doi.org/10.1172/JCI93566DS1.
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